Top

Hepatology International

Published in:

01-02-2022 | Hepatocellular Carcinoma | Letter to the Editor

Response to “Iodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria”

Authors: Chih-Horng Wu, Jia-Horng Kao

Published in: Hepatology International | Issue 1/2022

Excerpt

To the Editor: …

Wu C-H, Liang P-C, Su T-H, Lin M-C, Chang Y-H, Shih TT-F, et al. Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma. Hepatol Int. 2021;

Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370CrossRef

Shao Y-Y, Wang S-Y, Lin S-M, Chen K-Y, Tseng J-H, Ho M-C, et al. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2021;120:1051–1060CrossRef

Kim Y, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89–97CrossRef

Livraghi T, Lazzaroni S, Meloni F, Solbiati L. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2005;92:856–858CrossRef

Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. Am J Gastroenterol. 2012;107:569–577CrossRef

Kao W-Y, Su C-W, Chiou Y-Y, Chiu N-C, Liu C-A, Fang K-C, et al. Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. Radiology Radiological Society of North America. 2017;285:670–680

Su T-H, Hu T-H, Chen C-Y, Huang Y-H, Chuang W-L, Lin C-C, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755–1764CrossRef

Hsu S-J, Yang S-S, Kao J-H. Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? J Formos Med Assoc. 2020;119:3–11CrossRef

Title: Response to “Iodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria”
Authors: Chih-Horng Wu
Jia-Horng Kao
Publication date: 01-02-2022
Publisher: Springer India
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Hepatology International / Issue 1/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-021-10272-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer

GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial

Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria

Reciprocal alterations in circulating and hepatic gamma–delta T cells in patients with primary biliary cholangitis

Non-alcoholic fatty liver disease in cerebrovascular disease: a bystander or a real risk factor?

Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials